MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.51 (-1.00%)

Growth Price

Overvalued by 31.19%

Stability Price

Overvalued by 60.25%

Company Metrics

  • P/E 14.74
  • P/S 3.57
  • P/B 3.10
  • EPS 3.42
  • Cash ROIC 12.10%
  • Cash Ratio 0.84
  • Dividend 1.80 / 3.51 %
  • Avg. Vol. 12.19M
  • Shares 2.82B
  • Market Cap. 142.07B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Merck and Co Latest FDA Approval Looks Good: UBS
Bidness ETC - Oct 7, 2015
Merck & Co., Inc. (NYSE:MRK) received a second approval for its immune-oncology drug, Keytruda. Last week the Food and Drug Administration (FDA) granted expanded approval to Keytruda for treating the most common form of lung cancer, both squamous ...
FDA Expands Approval Of Merck's Keytruda To Lung Cancer - Medical Daily
FDA Approves Merck's Keytruda for Advanced Lung Cancer - Tech Times
Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc ...
PR Newswire (press release) - 6 hours ago
ADELAIDE, Australia, Oct. 8, 2015 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous ...
REFILE-BRIEF-Bionomics announces extension of strategic collaboration with ... - Reuters
Bionomics, Merck extend collaboration to develop drug candidates for treatment ... -
Zacks Short Term Rating on Merck & Company, Inc. (NYSE:MRK)
News Watch International - 10 hours ago
Merck & Company, Inc. (NYSE:MRK) has received a short term rating of sell from research analysts at Zacks with a rank of 4. The company has been rated an average of 2 by 14 Wall Street Analysts.
Large Inflow of Money Witnessed in Merck & Company, Inc. - American Trade Journal
Merck & Co. Lowered to Sell at Zacks (MRK) - Dakota Financial News
Are Amgen, Inc. And Merck and Co CETP A Threat To PCSK-9
Bidness ETC - 1 hour ago
Amgen Inc. (NASDAQ:AMGN) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) recently revolutionized the cholesterol market with their new treatments, which belong to the new class of drugs called PCSK9 inhibitors.
See Which Of The Latest 13F Filers Holds Merck & Co.
Nasdaq - 19 hours ago
At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2015 reporting period, and noticed that Merck & Co., Inc (Symbol: MRK) was held by 13 of these funds. When hedge fund managers appear to be thinking ...
Movements of Healthcare Stocks: Merck & Co., Inc. (NYSE:MRK), Eli Lilly (NYSE ...
Wsnews4investors - 3 hours ago
At the time of Market beginning, Merck & Co., Inc. (NYSE:MRK) initiated business at $50.46. The company rose 2.31% after overall traded volume of 14.54 million shares with market capitalization of $140.27 billion.
Fear These 3 Biotech Stocks: Merck & Co. Inc. (NYSE:MRK), Eli Lilly and ... - Seneca Globe
Merck & Company, Inc. (NYSE:MRK) Analyst Price Target
Money Flow Index - Oct 6, 2015
Merck & Company, Inc. (NYSE:MRK) should head towards $64.91 per share according to 11 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $57 per share.
Company Shares of Merck & Company, Inc. (NYSE:MRK) Rally 1.09% - News Watch International
Merck & Co. Coverage Initiated by Analysts at Societe Generale (MRK) - The Legacy
Pfizer Inc, Merck and Co. Also To Blame For US Drug Price Hikes
Bidness ETC - 2 hours ago
An exorbitant price hike by a small, obscure biotech, Turing Pharmaceutical, triggered a massive political debate on specialty pharma drug pricing in the last week of September.
Why Alibaba Group Holding Ltd (BABA), Merck & Co., Inc. (MRK) and BioMarin ... - Sep 21, 2015
It wasn't a bullish day for all stocks, though. Merck & Co., Inc. (NYSE:MRK), Alibaba Group Holding Ltd (NYSE:BABA) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) all used more than their fair share of red ink on the first day of the new trading week.
This Coule Be Merck & Co., Inc. (MRK)'s Most Important News Today - Oct 2, 2015
Merck & Company (MRK) shares inched lower in trading Friday despite a move by the U.S. Food and Drug Administration to grant accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced non-small cell lung cancer.